The United States stands at a historic, potentially decisive crossroads for cannabis policy.
Public transcripts and filings from the DEA rescheduling hearing recently revealed the agency’s official brief, which strongly advocates for moving cannabis to Schedule III. Seeing this pro-medical stance formally signed by the DEA Administrator marks a stunning reversal after decades of strict opposition.
In the coming weeks, a DEA Administrative Law Judge will issue a non-binding opinion. This recommendation will likely provide the necessary administrative cover for the DEA to finalize the rescheduling. Although lawsuits will inevitably follow, the policy shift will likely take effect while those legal battles play out.
The ultimate impact remains uncertain. State legislatures and courts will still need to determine exactly what this change means for:
State medical programs
Patients nationwide
Licensed cannabis businesses
The broader industry
Furthermore, cannabis and its natural extracts arguably do not belong on the controlled substances schedule at all.
Simultaneously, Congress faces a looming pre-election deadline to either delay, modify, or maintain the upcoming “hemp” ban. This forces a cornered hand for states that previously ignored or lightly regulated intoxicating cannabinoids. They now face immense pressure to act.
Local governments will likely respond in one of three ways:
Legalizing and regulating adult-use sales
Expanding existing medical programs
Doubling down on prohibition through low-income community arrests
As these shifting dynamics begin to unfold, turn into reality, and reshape the legal landscape, our fingers are crossed that this happens. Research is currently not being done on medical cannabis and it’s benefits in the United States because of this DEA scheduling.